A combination of ciprofloxacin and Rowachol does not prevent biliary stent occlusion.
BACKGROUND
Endoscopic insertion of biliary prostheses is now an established palliative treatment for frail and elderly patients with distal extrahepatic malignant biliary strictures who are unable to tolerate major surgery. The major limitation to long-term biliary stenting is late stent occlusion caused by bacterial adherence followed by encrustation with amorphous bacterial products. We studied the effect on the duration of stent patency of combination therapy with ciprofloxacin and Rowachol, a choleretic agent, in a group of patients who underwent stent insertion for extrahepatic malignant biliary strictures.


METHODS
Patients with this diagnosis were randomized to either active treatment with ciprofloxacin (500 mg twice daily) and Rowachol (2 tablets 3 times daily) or no drug treatment (control group). They were followed up prospectively and the end points of the study were stent occlusion and patient survival.


RESULTS
Forty-eight patients who had successful stent placement were recruited; 8 patients were excluded from the final analysis because of death in less than 1 month (5 patients) or stent replacement within a month because of persistent jaundice (3 patients). Twenty patients were randomized to the active and control groups. One patient in the active group withdrew because of nausea. The 2 groups were comparable with regard to age, gender, causes of extrahepatic malignant biliary strictures, and levels of serum alkaline phosphatase and bilirubin. There were significant reductions in mean serum bilirubin and alkaline phosphatase concentrations 1 month after stent placement. At the time of analysis, 12 patients were still alive (7 patients from the control group). Median survival was 23 weeks in both the active treatment group and the control group. There were 9 episodes (45%) of stent occlusions in the active treatment group and 10 episodes (50%) in the control group. The median time to stent occlusion was 23 (range 7 to 68) weeks for the active treatment group and 21 (range 6 to 56) weeks for the control group, p = 0.23. There was no significant difference in the duration of patient survival and of stent patency between the 2 groups. The lack of difference between treated and untreated patients in survival duration and stent patency was also shown if the results were analyzed on an intent-to-treat basis and the 8 patients who were excluded in the final analysis were also analyzed.


CONCLUSIONS
Prophylactic therapy with ciprofloxacin and Rowachol does not prolong stent patency or patient survival.
Luman
W
W
Gastrointestinal Unit, Western General Hospital, Edinburgh, United Kingdom.
Ghosh
S
S
Palmer
K R
KR
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D001650:Bile Duct Neoplasms / Q000150:complications; D001663:Bilirubin / Q000097:blood; D002756:Cholagogues and Choleretics / Q000008:administration & dosage*; D002779:Cholestasis / Q000401:mortality / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004868:Equipment Failure; D005260:Female; D005500:Follow-Up Studies; D016330:Frail Elderly; D006801:Humans; D008297:Male; D039821:Monoterpenes; D011446:Prospective Studies; D015607:Stents; D015996:Survival Rate; D013729:Terpenes / Q000008:administration & dosage*
D000890:Anti-Infective Agents; D002756:Cholagogues and Choleretics; D004338:Drug Combinations; D039821:Monoterpenes; D013729:Terpenes; D002939:Ciprofloxacin; C018655:Rowachol; D000469:Alkaline Phosphatase; D001663:Bilirubin